Merck and Ridgeback ’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

KENILWORTH, N.J.& MIAMI--(BUSINESS WIRE) December 23, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials